Gsk (GLAXF) Net Cash Flow (2009 - 2026)

Gsk's Net Cash Flow history runs 18 years deep, the most recent figure standing at $210.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 83.55% year-over-year to $210.3 million; the TTM figure through Mar 2026 stood at -$191.4 million (down 108.53% YoY), while the FY2025 annual figure was -$233.4 million, down 130.48% from the prior year.
• Net Cash Flow was $210.3 million for Q1 2026 at Gsk, up from -$401.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $9.3 billion in Q1 2022 to a low of -$533.6 million in Q1 2023.
• Historically, Net Cash Flow has averaged $1.5 billion across 5 years, with a median of $307.8 million in 2023.
• Biggest YoY gain for Net Cash Flow was 1314.2% in 2025; the steepest drop was 141.56% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $2.1 billion in 2022, then tumbled by 85.38% to $307.8 million in 2023, then soared by 213.99% to $966.5 million in 2024, then sank by 141.56% to -$401.7 million in 2025, then jumped by 152.36% to $210.3 million in 2026.
• The last three Net Cash Flow figures came in at $210.3 million (Q1 2026), -$401.7 million (Q4 2025), and $1.3 billion (Q1 2025), per Business Quant data.